Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
Relapsed NLPHL
DRUG: Ofatumumab
Overall response rate, 12 months after end of treatment
duration of response, 12 months after end of treatment|Progression free survival, 12 months after end of treatment|adverse events, 12 months after end of treatment
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).